Key facts
- Cristalens’s last known valuation is $19.4M (Jul 2025).
- It has raised $1.0M; the latest was Later Stage VC ($1.0M) in Jul 2025.
- Notable investors include Bpifrance, European Innovation Council, Horizon 2020, Region of Brittany.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Cristalens
- ·The full record, as it builds
Funding rounds
No funding rounds for Cristalens are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cristalens
Manufacturer of intraocular lenses intended to replace the eye's natural lens that is removed during cataract surgery. The company's lenses are implanted in the eye as part of a treatment for cataracts or myopia and are permanently fixated inside the eye, allowing patients to focus at one fixed distance to restore both near and distant vision.
- Sector
- Healthcare
- HQ
- Eragny, France
- Founded
- 1994
- Employees
- 51
- Ownership
- Privately Held (backing)
Cristalens doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cristalens shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cristalens in its N-PORT filings yet. We sweep new filings monthly.